Cargando…
Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells
Chemotherapy using temozolomide is the standard treatment for patients with glioblastoma. Despite treatment, prognosis is still poor largely due to the emergence of temozolomide resistance. This resistance is closely linked to the widely recognized inter- and intra-tumoral heterogeneity in glioblast...
Autores principales: | Fabro, Federica, Kers, Trisha V., Feller, Kate J., Beerens, Cecile, Ntafoulis, Ioannis, Idbaih, Ahmed, Verreault, Maite, Connor, Kate, Biswas, Archita, Salvucci, Manuela, Prehn, Jochen H. M., Byrne, Annette T., O’Farrell, Alice C., Lambrechts, Diether, Dilcan, Gonca, Lodi, Francesca, Arijs, Ingrid, Kremer, Andreas, Tching Chi Yen, Romain, Chien, Miao-Ping, Lamfers, Martine L. M., Leenstra, Sieger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647455/ https://www.ncbi.nlm.nih.gov/pubmed/37958662 http://dx.doi.org/10.3390/ijms242115678 |
Ejemplares similares
-
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers
por: Ntafoulis, Ioannis, et al.
Publicado: (2023) -
Comparative analysis of deeply phenotyped GBM cohorts of ‘short-term’ and ‘long-term’ survivors
por: Biswas, Archita, et al.
Publicado: (2023) -
Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
por: Ntafoulis, Ioannis, et al.
Publicado: (2022) -
Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
por: Fabro, Federica, et al.
Publicado: (2022) -
Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
por: Verheul, Cassandra, et al.
Publicado: (2021)